Neurosigma Inc (Neurosigma) is a life science company that develops and commercializes trigeminal nerve stimulation technologies for neurologic and psychiatric disorders. The company offers treatments for epilepsy, depression, attention deficit hyperactivity disorder, and post-traumatic stress disorder. It also conducts preclinical research and development, and phase clinical trials. Neurosigma offers Monarch eTNS System for the treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD). The company's trigeminal nerve stimulation has been investigated as a therapy for epilepsy, depression, attention deficit hyperactivity disorder, and post-traumatic stress disorder, Lennox-Gastaut syndrome and traumatic brain injuries, among others. NeuroSigma is headquartered in Los Angeles, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Neurosigma Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Neurosigma Inc Company Overview
Neurosigma Inc Company Snapshot
Neurosigma Inc Pipeline Products and Ongoing Clinical Trials Overview
Neurosigma Inc – Pipeline Analysis Overview
Neurosigma Inc - Key Facts
Neurosigma Inc - Major Products and Services
Neurosigma Inc Pipeline Products by Development Stage
Neurosigma Inc Ongoing Clinical Trials by Trial Status
Neurosigma Inc Pipeline Products Overview
Deep Brain Stimulation System - Cachexia
Deep Brain Stimulation System - Cachexia Product Overview
Deep Brain Stimulation System - Obesity
Deep Brain Stimulation System - Obesity Product Overview
DELTA Stent
DELTA Stent Product Overview
Generation 2.0 Monarch external Trigeminal Nerve Stimulation (eTNS) System
Monarch eTNS System - Lennox-Gastaut Syndrome Product Overview
Monarch eTNS System - Post-Traumatic Stress Disorder
Monarch eTNS System - Post-Traumatic Stress Disorder Product Overview
Monarch eTNS System - Traumatic Brain Injury
Monarch eTNS System - Traumatic Brain Injury Product Overview
Next-Generation eTNS System
Next-Generation eTNS System Product Overview
sTNS System - Epilepsy
sTNS System - Epilepsy Product Overview
Thin Film Nitinol Flow Diverting Stent
Thin Film Nitinol Flow Diverting Stent Product Overview
Neurosigma Inc - Key Competitors
Neurosigma Inc - Key Employees
Neurosigma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Neurosigma Inc, Recent Developments
Jan 18, 2024: NeuroSigma gets green light from FDA for ADHD wearable
Nov 07, 2023: NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
Mar 01, 2023: NeuroSigma announces new telehealth option for patients and caregivers interested in eTNS for pediatric ADHD
Jan 31, 2023: NeuroSigma announces strategic digital marketing partnership with Data360
Nov 08, 2022: NeuroSigma announces that enrollment commences in two large, double-blind trials of eTNS for Pediatric ADHD
Oct 17, 2022: NeuroSigma announces commercial launch of the Monarch eTNS System for the treatment of pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry
Sep 27, 2022: NeuroSigma announces receipt of permanent HCPCS codes from CMS for Monarch eTNS System
Jun 14, 2022: NeuroSigma announces that a team led by UCLA researchers receives NIH grant to conduct a multicenter trial of eTNS for pediatric ADHD
Apr 07, 2022: NeuroSigma announces King’s College London Team receives MHRA approval to commence largest clinical trial of eTNS for Pediatric ADHD to Date
Feb 22, 2022: NeuroSigma receives FDA Breakthrough Device Designation for Monarch eTNS System
Table 20: Monarch eTNS System - ADHD - Product Status
Table 21: Monarch eTNS System - ADHD - Product Description
Table 22: Monarch eTNS System - ADHD - A Multi-centre, Double-blind, Randomized, Parallel-group, Phase IIb Study to Compare the Efficacy of Real Versus Sham External Trigeminal Nerve Stimulation on Symptoms in Youth with Attention Deficit Hyperactivity Disorder
Table 23: Monarch eTNS System - ADHD - Efficacy of External Trigeminal Nerve Stimulation for Treatment of ADHD
Table 24: Monarch eTNS System - Depression - Product Status
Table 25: Monarch eTNS System - Depression - Product Description
Table 26: Monarch eTNS System - Epilepsy - Product Status
Table 27: Monarch eTNS System - Epilepsy - Product Description
Table 28: Monarch eTNS System - Lennox-Gastaut Syndrome - Product Status